Company / PP&E (Net)
Adaptimmune Therapeutics PLC PP&E (Net) History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$31.3M
FY2024
5-year range
$27.8M / $53.5M
FY2020-FY2024
Trend
-38.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 9 years, ranging from $28M in FY2020 to $54M in FY2022.
Based on SEC 10-K filings.
$31M in FY2024 with a 5-year CAGR of +0.2%.
Declined from $54M to $31M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +0.9%
- 5-Year CAGR
- +0.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.2%, indicating consistent growth.
- In FY2024, pp&e (net) decreased 38.5% year-over-year.
- Peak pp&e (net) was recorded in FY2022.
- Lowest pp&e (net) in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $31.3M | -38.5% |
| FY2023 | $50.9M | -4.8% |
| FY2022 | $53.5M | +75.5% |
| FY2021 | $30.5M | +9.8% |
| FY2020 | $27.8M | -10.6% |
| FY2019 | $31.1M | -14.0% |
| FY2018 | $36.1M | -11.2% |
| FY2017 | $40.7M | +45.8% |
| FY2016 | $27.9M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026